Accolade, Inc.
Get $10 bonus on your first $100 deposit for ACCD
Get $10 bonus on your first $100 deposit for ACCD
Accolade, Inc. (ACCD) Stock Competitors & Peer Comparison
See (ACCD) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ACCD | $7.02 | +0.00% | 575.6M | -3.08 | -$2.28 | N/A |
| GEHC | $70.35 | -2.26% | 32.1B | 15.46 | $4.55 | +0.20% |
| VEEV | $174.07 | +0.77% | 28.6B | 32.00 | $5.44 | N/A |
| BTSGU | $143.86 | -0.57% | 27.8B | N/A | N/A | N/A |
| GEHCV | $56.00 | -4.08% | 25.5B | N/A | N/A | N/A |
| SGFY | $30.49 | +0.07% | 8.9B | 70.91 | $0.43 | N/A |
| BTSG | $43.10 | +2.55% | 8.3B | 89.79 | $0.48 | N/A |
| TEM | $47.39 | +0.77% | 8.2B | -33.61 | -$1.41 | N/A |
| HQY | $84.67 | +1.55% | 7.2B | 34.42 | $2.46 | N/A |
| RCM | $14.31 | N/A | 6B | -102.21 | -$0.14 | N/A |
Stock Comparison
ACCD vs GEHC Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, GEHC has a market cap of 32.1B. Regarding current trading prices, ACCD is priced at $7.02, while GEHC trades at $70.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas GEHC's P/E ratio is 15.46. In terms of profitability, ACCD's ROE is -0.22%, compared to GEHC's ROE of +0.17%. Regarding short-term risk, ACCD is less volatile compared to GEHC. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check GEHC's competition here
ACCD vs VEEV Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, VEEV has a market cap of 28.6B. Regarding current trading prices, ACCD is priced at $7.02, while VEEV trades at $174.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas VEEV's P/E ratio is 32.00. In terms of profitability, ACCD's ROE is -0.22%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, ACCD is less volatile compared to VEEV. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check VEEV's competition here
ACCD vs BTSGU Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, BTSGU has a market cap of 27.8B. Regarding current trading prices, ACCD is priced at $7.02, while BTSGU trades at $143.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas BTSGU's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to BTSGU's ROE of +0.11%. Regarding short-term risk, ACCD is less volatile compared to BTSGU. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check BTSGU's competition here
ACCD vs GEHCV Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, ACCD is priced at $7.02, while GEHCV trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas GEHCV's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to GEHCV's ROE of +0.21%. Regarding short-term risk, ACCD is less volatile compared to GEHCV. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check GEHCV's competition here
ACCD vs SGFY Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, ACCD is priced at $7.02, while SGFY trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SGFY's P/E ratio is 70.91. In terms of profitability, ACCD's ROE is -0.22%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, ACCD is less volatile compared to SGFY. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check SGFY's competition here
ACCD vs BTSG Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, BTSG has a market cap of 8.3B. Regarding current trading prices, ACCD is priced at $7.02, while BTSG trades at $43.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas BTSG's P/E ratio is 89.79. In terms of profitability, ACCD's ROE is -0.22%, compared to BTSG's ROE of +0.11%. Regarding short-term risk, ACCD is less volatile compared to BTSG. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check BTSG's competition here
ACCD vs TEM Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, TEM has a market cap of 8.2B. Regarding current trading prices, ACCD is priced at $7.02, while TEM trades at $47.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas TEM's P/E ratio is -33.61. In terms of profitability, ACCD's ROE is -0.22%, compared to TEM's ROE of -0.60%. Regarding short-term risk, ACCD is less volatile compared to TEM. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check TEM's competition here
ACCD vs HQY Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, HQY has a market cap of 7.2B. Regarding current trading prices, ACCD is priced at $7.02, while HQY trades at $84.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas HQY's P/E ratio is 34.42. In terms of profitability, ACCD's ROE is -0.22%, compared to HQY's ROE of +0.10%. Regarding short-term risk, ACCD is less volatile compared to HQY. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check HQY's competition here
ACCD vs RCM Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, ACCD is priced at $7.02, while RCM trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas RCM's P/E ratio is -102.21. In terms of profitability, ACCD's ROE is -0.22%, compared to RCM's ROE of +0.00%. Regarding short-term risk, ACCD and RCM have similar daily volatility (0.00).Check RCM's competition here
ACCD vs DOCS Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, DOCS has a market cap of 4.3B. Regarding current trading prices, ACCD is priced at $7.02, while DOCS trades at $22.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas DOCS's P/E ratio is 19.13. In terms of profitability, ACCD's ROE is -0.22%, compared to DOCS's ROE of +0.23%. Regarding short-term risk, ACCD is less volatile compared to DOCS. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check DOCS's competition here
ACCD vs ONEM Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, ACCD is priced at $7.02, while ONEM trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas ONEM's P/E ratio is -7.77. In terms of profitability, ACCD's ROE is -0.22%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, ACCD is less volatile compared to ONEM. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check ONEM's competition here
ACCD vs HNGE Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, HNGE has a market cap of 3.1B. Regarding current trading prices, ACCD is priced at $7.02, while HNGE trades at $38.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas HNGE's P/E ratio is -5.02. In terms of profitability, ACCD's ROE is -0.22%, compared to HNGE's ROE of -1.32%. Regarding short-term risk, ACCD is less volatile compared to HNGE. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check HNGE's competition here
ACCD vs TXG Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, TXG has a market cap of 2.9B. Regarding current trading prices, ACCD is priced at $7.02, while TXG trades at $22.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas TXG's P/E ratio is -63.80. In terms of profitability, ACCD's ROE is -0.22%, compared to TXG's ROE of -0.06%. Regarding short-term risk, ACCD is less volatile compared to TXG. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check TXG's competition here
ACCD vs PRVA Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, PRVA has a market cap of 2.6B. Regarding current trading prices, ACCD is priced at $7.02, while PRVA trades at $21.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas PRVA's P/E ratio is 117.83. In terms of profitability, ACCD's ROE is -0.22%, compared to PRVA's ROE of +0.03%. Regarding short-term risk, ACCD is less volatile compared to PRVA. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check PRVA's competition here
ACCD vs PINC Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, PINC has a market cap of 2.3B. Regarding current trading prices, ACCD is priced at $7.02, while PINC trades at $28.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas PINC's P/E ratio is 166.24. In terms of profitability, ACCD's ROE is -0.22%, compared to PINC's ROE of -0.02%. Regarding short-term risk, ACCD and PINC have similar daily volatility (0.00).Check PINC's competition here
ACCD vs HTFL Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, HTFL has a market cap of 2.1B. Regarding current trading prices, ACCD is priced at $7.02, while HTFL trades at $24.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas HTFL's P/E ratio is -7.83. In terms of profitability, ACCD's ROE is -0.22%, compared to HTFL's ROE of +0.38%. Regarding short-term risk, ACCD is less volatile compared to HTFL. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check HTFL's competition here
ACCD vs WGS Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, WGS has a market cap of 1.9B. Regarding current trading prices, ACCD is priced at $7.02, while WGS trades at $66.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas WGS's P/E ratio is -90.68. In terms of profitability, ACCD's ROE is -0.22%, compared to WGS's ROE of -0.07%. Regarding short-term risk, ACCD is less volatile compared to WGS. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check WGS's competition here
ACCD vs NXGN Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, ACCD is priced at $7.02, while NXGN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas NXGN's P/E ratio is -266.00. In terms of profitability, ACCD's ROE is -0.22%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, ACCD is less volatile compared to NXGN. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check NXGN's competition here
ACCD vs OMCL Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, OMCL has a market cap of 1.6B. Regarding current trading prices, ACCD is priced at $7.02, while OMCL trades at $34.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas OMCL's P/E ratio is 853.75. In terms of profitability, ACCD's ROE is -0.22%, compared to OMCL's ROE of +0.00%. Regarding short-term risk, ACCD is less volatile compared to OMCL. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check OMCL's competition here
ACCD vs AGTI Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, ACCD is priced at $7.02, while AGTI trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas AGTI's P/E ratio is -71.79. In terms of profitability, ACCD's ROE is -0.22%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, ACCD is less volatile compared to AGTI. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check AGTI's competition here
ACCD vs PGNY Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, PGNY has a market cap of 1.4B. Regarding current trading prices, ACCD is priced at $7.02, while PGNY trades at $16.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas PGNY's P/E ratio is 25.54. In terms of profitability, ACCD's ROE is -0.22%, compared to PGNY's ROE of +0.11%. Regarding short-term risk, ACCD is less volatile compared to PGNY. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check PGNY's competition here
ACCD vs TDOC Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, TDOC has a market cap of 940.1M. Regarding current trading prices, ACCD is priced at $7.02, while TDOC trades at $5.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas TDOC's P/E ratio is -0.15. In terms of profitability, ACCD's ROE is -0.22%, compared to TDOC's ROE of -0.14%. Regarding short-term risk, ACCD is less volatile compared to TDOC. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check TDOC's competition here
ACCD vs CERT Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, CERT has a market cap of 861.7M. Regarding current trading prices, ACCD is priced at $7.02, while CERT trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas CERT's P/E ratio is -541.00. In terms of profitability, ACCD's ROE is -0.22%, compared to CERT's ROE of -0.00%. Regarding short-term risk, ACCD is less volatile compared to CERT. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check CERT's competition here
ACCD vs SDGR Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SDGR has a market cap of 854.9M. Regarding current trading prices, ACCD is priced at $7.02, while SDGR trades at $11.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SDGR's P/E ratio is -8.21. In terms of profitability, ACCD's ROE is -0.22%, compared to SDGR's ROE of -0.29%. Regarding short-term risk, ACCD is less volatile compared to SDGR. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check SDGR's competition here
ACCD vs CCLDO Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, CCLDO has a market cap of 804.5M. Regarding current trading prices, ACCD is priced at $7.02, while CCLDO trades at $25.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas CCLDO's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to CCLDO's ROE of +0.19%. Regarding short-term risk, ACCD is less volatile compared to CCLDO. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check CCLDO's competition here
ACCD vs OMDA Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, OMDA has a market cap of 741.3M. Regarding current trading prices, ACCD is priced at $7.02, while OMDA trades at $12.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas OMDA's P/E ratio is -35.94. In terms of profitability, ACCD's ROE is -0.22%, compared to OMDA's ROE of -0.07%. Regarding short-term risk, ACCD is less volatile compared to OMDA. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check OMDA's competition here
ACCD vs GDRX Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, GDRX has a market cap of 702.5M. Regarding current trading prices, ACCD is priced at $7.02, while GDRX trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas GDRX's P/E ratio is 22.78. In terms of profitability, ACCD's ROE is -0.22%, compared to GDRX's ROE of +0.05%. Regarding short-term risk, ACCD is less volatile compared to GDRX. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check GDRX's competition here
ACCD vs MPLN-WT Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, ACCD is priced at $7.02, while MPLN-WT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to MPLN-WT's ROE of +3.78%. Regarding short-term risk, ACCD is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check MPLN-WT's competition here
ACCD vs HSTM Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, HSTM has a market cap of 606.7M. Regarding current trading prices, ACCD is priced at $7.02, while HSTM trades at $20.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas HSTM's P/E ratio is 33.52. In terms of profitability, ACCD's ROE is -0.22%, compared to HSTM's ROE of +0.05%. Regarding short-term risk, ACCD is less volatile compared to HSTM. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check HSTM's competition here
ACCD vs NUTX Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, NUTX has a market cap of 600.9M. Regarding current trading prices, ACCD is priced at $7.02, while NUTX trades at $100.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas NUTX's P/E ratio is 9.63. In terms of profitability, ACCD's ROE is -0.22%, compared to NUTX's ROE of +0.24%. Regarding short-term risk, ACCD is less volatile compared to NUTX. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check NUTX's competition here
ACCD vs SHCR Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, ACCD is priced at $7.02, while SHCR trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SHCR's P/E ratio is -3.76. In terms of profitability, ACCD's ROE is -0.22%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, ACCD is less volatile compared to SHCR. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check SHCR's competition here
ACCD vs PHR Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, PHR has a market cap of 504.6M. Regarding current trading prices, ACCD is priced at $7.02, while PHR trades at $8.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas PHR's P/E ratio is 209.25. In terms of profitability, ACCD's ROE is -0.22%, compared to PHR's ROE of -0.07%. Regarding short-term risk, ACCD is less volatile compared to PHR. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check PHR's competition here
ACCD vs SLGCW Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, ACCD is priced at $7.02, while SLGCW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, ACCD's ROE is -0.22%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, ACCD is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check SLGCW's competition here
ACCD vs SLGC Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, ACCD is priced at $7.02, while SLGC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SLGC's P/E ratio is -3.04. In terms of profitability, ACCD's ROE is -0.22%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, ACCD is less volatile compared to SLGC. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check SLGC's competition here
ACCD vs NRC Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, NRC has a market cap of 390.3M. Regarding current trading prices, ACCD is priced at $7.02, while NRC trades at $17.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas NRC's P/E ratio is 34.32. In terms of profitability, ACCD's ROE is -0.22%, compared to NRC's ROE of +0.59%. Regarding short-term risk, ACCD is less volatile compared to NRC. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check NRC's competition here
ACCD vs SY Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SY has a market cap of 377.7M. Regarding current trading prices, ACCD is priced at $7.02, while SY trades at $2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SY's P/E ratio is -8.20. In terms of profitability, ACCD's ROE is -0.22%, compared to SY's ROE of -0.14%. Regarding short-term risk, ACCD is less volatile compared to SY. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check SY's competition here
ACCD vs MPLN Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, ACCD is priced at $7.02, while MPLN trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas MPLN's P/E ratio is -0.23. In terms of profitability, ACCD's ROE is -0.22%, compared to MPLN's ROE of +3.78%. Regarding short-term risk, ACCD is less volatile compared to MPLN. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check MPLN's competition here
ACCD vs SOPH Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SOPH has a market cap of 361.2M. Regarding current trading prices, ACCD is priced at $7.02, while SOPH trades at $5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SOPH's P/E ratio is -4.31. In terms of profitability, ACCD's ROE is -0.22%, compared to SOPH's ROE of -1.17%. Regarding short-term risk, ACCD is less volatile compared to SOPH. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check SOPH's competition here
ACCD vs CTEV Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, CTEV has a market cap of 289M. Regarding current trading prices, ACCD is priced at $7.02, while CTEV trades at $17.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas CTEV's P/E ratio is -1.01. In terms of profitability, ACCD's ROE is -0.22%, compared to CTEV's ROE of +3.78%. Regarding short-term risk, ACCD is less volatile compared to CTEV. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check CTEV's competition here
ACCD vs TRHC Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, ACCD is priced at $7.02, while TRHC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas TRHC's P/E ratio is -4.27. In terms of profitability, ACCD's ROE is -0.22%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, ACCD is less volatile compared to TRHC. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check TRHC's competition here
ACCD vs CARL Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, CARL has a market cap of 260.1M. Regarding current trading prices, ACCD is priced at $7.02, while CARL trades at $9.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas CARL's P/E ratio is -4.59. In terms of profitability, ACCD's ROE is -0.22%, compared to CARL's ROE of -2.64%. Regarding short-term risk, ACCD is less volatile compared to CARL. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check CARL's competition here
ACCD vs EVH Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, EVH has a market cap of 251.2M. Regarding current trading prices, ACCD is priced at $7.02, while EVH trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas EVH's P/E ratio is -0.44. In terms of profitability, ACCD's ROE is -0.22%, compared to EVH's ROE of -0.69%. Regarding short-term risk, ACCD is less volatile compared to EVH. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check EVH's competition here
ACCD vs SMFR Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, ACCD is priced at $7.02, while SMFR trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SMFR's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to SMFR's ROE of -0.07%. Regarding short-term risk, ACCD is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check SMFR's competition here
ACCD vs TBRG Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, TBRG has a market cap of 243.7M. Regarding current trading prices, ACCD is priced at $7.02, while TBRG trades at $16.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas TBRG's P/E ratio is 56.00. In terms of profitability, ACCD's ROE is -0.22%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, ACCD is less volatile compared to TBRG. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check TBRG's competition here
ACCD vs SLP Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SLP has a market cap of 241.6M. Regarding current trading prices, ACCD is priced at $7.02, while SLP trades at $11.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SLP's P/E ratio is -3.75. In terms of profitability, ACCD's ROE is -0.22%, compared to SLP's ROE of -0.45%. Regarding short-term risk, ACCD is less volatile compared to SLP. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check SLP's competition here
ACCD vs SPOK Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SPOK has a market cap of 230.7M. Regarding current trading prices, ACCD is priced at $7.02, while SPOK trades at $11.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SPOK's P/E ratio is 14.84. In terms of profitability, ACCD's ROE is -0.22%, compared to SPOK's ROE of +0.11%. Regarding short-term risk, ACCD is less volatile compared to SPOK. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check SPOK's competition here
ACCD vs CCLD Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, CCLD has a market cap of 142.4M. Regarding current trading prices, ACCD is priced at $7.02, while CCLD trades at $3.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas CCLD's P/E ratio is 33.50. In terms of profitability, ACCD's ROE is -0.22%, compared to CCLD's ROE of +0.19%. Regarding short-term risk, ACCD is less volatile compared to CCLD. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check CCLD's competition here
ACCD vs CPSI Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, ACCD is priced at $7.02, while CPSI trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas CPSI's P/E ratio is -183.80. In terms of profitability, ACCD's ROE is -0.22%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, ACCD is less volatile compared to CPSI. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check CPSI's competition here
ACCD vs OPRX Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, OPRX has a market cap of 123.1M. Regarding current trading prices, ACCD is priced at $7.02, while OPRX trades at $6.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas OPRX's P/E ratio is 24.30. In terms of profitability, ACCD's ROE is -0.22%, compared to OPRX's ROE of +0.04%. Regarding short-term risk, ACCD is less volatile compared to OPRX. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check OPRX's competition here
ACCD vs AUGX Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, ACCD is priced at $7.02, while AUGX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas AUGX's P/E ratio is -4.99. In terms of profitability, ACCD's ROE is -0.22%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, ACCD is less volatile compared to AUGX. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check AUGX's competition here
ACCD vs DH Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, DH has a market cap of 112.8M. Regarding current trading prices, ACCD is priced at $7.02, while DH trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas DH's P/E ratio is -0.83. In terms of profitability, ACCD's ROE is -0.22%, compared to DH's ROE of -0.47%. Regarding short-term risk, ACCD is less volatile compared to DH. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check DH's competition here
ACCD vs AMWL Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, AMWL has a market cap of 91M. Regarding current trading prices, ACCD is priced at $7.02, while AMWL trades at $5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas AMWL's P/E ratio is -0.92. In terms of profitability, ACCD's ROE is -0.22%, compared to AMWL's ROE of -0.36%. Regarding short-term risk, ACCD is less volatile compared to AMWL. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check AMWL's competition here
ACCD vs HCAT Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, HCAT has a market cap of 86.1M. Regarding current trading prices, ACCD is priced at $7.02, while HCAT trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas HCAT's P/E ratio is -0.46. In terms of profitability, ACCD's ROE is -0.22%, compared to HCAT's ROE of -0.55%. Regarding short-term risk, ACCD is less volatile compared to HCAT. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check HCAT's competition here
ACCD vs FORA Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, FORA has a market cap of 65.3M. Regarding current trading prices, ACCD is priced at $7.02, while FORA trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas FORA's P/E ratio is -23.33. In terms of profitability, ACCD's ROE is -0.22%, compared to FORA's ROE of -0.09%. Regarding short-term risk, ACCD is less volatile compared to FORA. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check FORA's competition here
ACCD vs CCLDP Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, ACCD is priced at $7.02, while CCLDP trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas CCLDP's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to CCLDP's ROE of +0.19%. Regarding short-term risk, ACCD and CCLDP have similar daily volatility (0.00).Check CCLDP's competition here
ACCD vs BEAT Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, BEAT has a market cap of 40.6M. Regarding current trading prices, ACCD is priced at $7.02, while BEAT trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas BEAT's P/E ratio is -1.90. In terms of profitability, ACCD's ROE is -0.22%, compared to BEAT's ROE of -5.71%. Regarding short-term risk, ACCD is less volatile compared to BEAT. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check BEAT's competition here
ACCD vs SNCE Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, ACCD is priced at $7.02, while SNCE trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SNCE's P/E ratio is -0.27. In terms of profitability, ACCD's ROE is -0.22%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, ACCD is less volatile compared to SNCE. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check SNCE's competition here
ACCD vs AKLI Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, ACCD is priced at $7.02, while AKLI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas AKLI's P/E ratio is -0.71. In terms of profitability, ACCD's ROE is -0.22%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, ACCD is less volatile compared to AKLI. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check AKLI's competition here
ACCD vs SHLT Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, ACCD is priced at $7.02, while SHLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SHLT's P/E ratio is -3.87. In terms of profitability, ACCD's ROE is -0.22%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, ACCD and SHLT have similar daily volatility (0.00).Check SHLT's competition here
ACCD vs SHCRW Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, ACCD is priced at $7.02, while SHCRW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, ACCD's ROE is -0.22%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, ACCD is less volatile compared to SHCRW. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check SHCRW's competition here
ACCD vs ONMD Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, ONMD has a market cap of 30.5M. Regarding current trading prices, ACCD is priced at $7.02, while ONMD trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas ONMD's P/E ratio is -15.50. In terms of profitability, ACCD's ROE is -0.22%, compared to ONMD's ROE of +0.41%. Regarding short-term risk, ACCD is less volatile compared to ONMD. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check ONMD's competition here
ACCD vs STRM Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, ACCD is priced at $7.02, while STRM trades at $5.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas STRM's P/E ratio is -2.40. In terms of profitability, ACCD's ROE is -0.22%, compared to STRM's ROE of -0.50%. Regarding short-term risk, ACCD and STRM have similar daily volatility (0.00).Check STRM's competition here
ACCD vs RNLX Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, ACCD is priced at $7.02, while RNLX trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas RNLX's P/E ratio is -0.33. In terms of profitability, ACCD's ROE is -0.22%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, ACCD is less volatile compared to RNLX. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check RNLX's competition here
ACCD vs LIFW Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, ACCD is priced at $7.02, while LIFW trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas LIFW's P/E ratio is -0.02. In terms of profitability, ACCD's ROE is -0.22%, compared to LIFW's ROE of +3.93%. Regarding short-term risk, ACCD and LIFW have similar daily volatility (0.00).Check LIFW's competition here
ACCD vs EUDA Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, EUDA has a market cap of 17.8M. Regarding current trading prices, ACCD is priced at $7.02, while EUDA trades at $9.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas EUDA's P/E ratio is 23.50. In terms of profitability, ACCD's ROE is -0.22%, compared to EUDA's ROE of +0.14%. Regarding short-term risk, ACCD is less volatile compared to EUDA. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check EUDA's competition here
ACCD vs BBLN Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, ACCD is priced at $7.02, while BBLN trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas BBLN's P/E ratio is -0.04. In terms of profitability, ACCD's ROE is -0.22%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, ACCD is less volatile compared to BBLN. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check BBLN's competition here
ACCD vs BFRG Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, BFRG has a market cap of 12.7M. Regarding current trading prices, ACCD is priced at $7.02, while BFRG trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas BFRG's P/E ratio is -1.90. In terms of profitability, ACCD's ROE is -0.22%, compared to BFRG's ROE of -2.73%. Regarding short-term risk, ACCD is less volatile compared to BFRG. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check BFRG's competition here
ACCD vs ETAO Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, ACCD is priced at $7.02, while ETAO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas ETAO's P/E ratio is -0.01. In terms of profitability, ACCD's ROE is -0.22%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, ACCD is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check ETAO's competition here
ACCD vs HLTH Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, ACCD is priced at $7.02, while HLTH trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas HLTH's P/E ratio is -0.02. In terms of profitability, ACCD's ROE is -0.22%, compared to HLTH's ROE of -0.90%. Regarding short-term risk, ACCD is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check HLTH's competition here
ACCD vs ZCMD Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, ZCMD has a market cap of 5.7M. Regarding current trading prices, ACCD is priced at $7.02, while ZCMD trades at $1.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas ZCMD's P/E ratio is -1.16. In terms of profitability, ACCD's ROE is -0.22%, compared to ZCMD's ROE of -0.08%. Regarding short-term risk, ACCD is less volatile compared to ZCMD. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check ZCMD's competition here
ACCD vs UPH Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, ACCD is priced at $7.02, while UPH trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas UPH's P/E ratio is -0.07. In terms of profitability, ACCD's ROE is -0.22%, compared to UPH's ROE of -1.05%. Regarding short-term risk, ACCD is less volatile compared to UPH. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check UPH's competition here
ACCD vs UPH-WT Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, ACCD is priced at $7.02, while UPH-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, ACCD is less volatile compared to UPH-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check UPH-WT's competition here
ACCD vs SCNX Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SCNX has a market cap of 4.6M. Regarding current trading prices, ACCD is priced at $7.02, while SCNX trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SCNX's P/E ratio is -0.11. In terms of profitability, ACCD's ROE is -0.22%, compared to SCNX's ROE of -2.36%. Regarding short-term risk, ACCD is less volatile compared to SCNX. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check SCNX's competition here
ACCD vs BEATW Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, BEATW has a market cap of 4.1M. Regarding current trading prices, ACCD is priced at $7.02, while BEATW trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas BEATW's P/E ratio is -0.24. In terms of profitability, ACCD's ROE is -0.22%, compared to BEATW's ROE of -5.71%. Regarding short-term risk, ACCD is less volatile compared to BEATW. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check BEATW's competition here
ACCD vs PEARW Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, ACCD is priced at $7.02, while PEARW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas PEARW's P/E ratio is -0.00. In terms of profitability, ACCD's ROE is -0.22%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, ACCD is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check PEARW's competition here
ACCD vs PEAR Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, ACCD is priced at $7.02, while PEAR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas PEAR's P/E ratio is -0.08. In terms of profitability, ACCD's ROE is -0.22%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, ACCD is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check PEAR's competition here
ACCD vs VSEE Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, VSEE has a market cap of 3.6M. Regarding current trading prices, ACCD is priced at $7.02, while VSEE trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas VSEE's P/E ratio is 0.48. In terms of profitability, ACCD's ROE is -0.22%, compared to VSEE's ROE of +6.29%. Regarding short-term risk, ACCD is less volatile compared to VSEE. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check VSEE's competition here
ACCD vs MGRX Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, MGRX has a market cap of 3.4M. Regarding current trading prices, ACCD is priced at $7.02, while MGRX trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas MGRX's P/E ratio is -0.16. In terms of profitability, ACCD's ROE is -0.22%, compared to MGRX's ROE of -1.17%. Regarding short-term risk, ACCD is less volatile compared to MGRX. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check MGRX's competition here
ACCD vs BFRGW Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, BFRGW has a market cap of 3.1M. Regarding current trading prices, ACCD is priced at $7.02, while BFRGW trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas BFRGW's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to BFRGW's ROE of -2.73%. Regarding short-term risk, ACCD is less volatile compared to BFRGW. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check BFRGW's competition here
ACCD vs HCTI Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, HCTI has a market cap of 2.9M. Regarding current trading prices, ACCD is priced at $7.02, while HCTI trades at $2.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas HCTI's P/E ratio is -0.03. In terms of profitability, ACCD's ROE is -0.22%, compared to HCTI's ROE of -1.13%. Regarding short-term risk, ACCD is less volatile compared to HCTI. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check HCTI's competition here
ACCD vs OTRK Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, ACCD is priced at $7.02, while OTRK trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas OTRK's P/E ratio is -0.02. In terms of profitability, ACCD's ROE is -0.22%, compared to OTRK's ROE of -2.04%. Regarding short-term risk, ACCD and OTRK have similar daily volatility (0.00).Check OTRK's competition here
ACCD vs ACON Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, ACON has a market cap of 1.9M. Regarding current trading prices, ACCD is priced at $7.02, while ACON trades at $3.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas ACON's P/E ratio is -0.26. In terms of profitability, ACCD's ROE is -0.22%, compared to ACON's ROE of -0.00%. Regarding short-term risk, ACCD is less volatile compared to ACON. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check ACON's competition here
ACCD vs CMAX Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, ACCD is priced at $7.02, while CMAX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas CMAX's P/E ratio is -0.00. In terms of profitability, ACCD's ROE is -0.22%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, ACCD and CMAX have similar daily volatility (0.00).Check CMAX's competition here
ACCD vs LIFWZ Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, ACCD is priced at $7.02, while LIFWZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to LIFWZ's ROE of +3.93%. Regarding short-term risk, ACCD and LIFWZ have similar daily volatility (0.00).Check LIFWZ's competition here
ACCD vs VSEEW Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, VSEEW has a market cap of 1.2M. Regarding current trading prices, ACCD is priced at $7.02, while VSEEW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas VSEEW's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to VSEEW's ROE of +6.29%. Regarding short-term risk, ACCD is less volatile compared to VSEEW. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check VSEEW's competition here
ACCD vs EUDAW Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, EUDAW has a market cap of 775.1K. Regarding current trading prices, ACCD is priced at $7.02, while EUDAW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas EUDAW's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to EUDAW's ROE of +0.14%. Regarding short-term risk, ACCD is less volatile compared to EUDAW. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check EUDAW's competition here
ACCD vs MSPRZ Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, ACCD is priced at $7.02, while MSPRZ trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to MSPRZ's ROE of +3.93%. Regarding short-term risk, ACCD is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check MSPRZ's competition here
ACCD vs WORX Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, WORX has a market cap of 490.1K. Regarding current trading prices, ACCD is priced at $7.02, while WORX trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas WORX's P/E ratio is -0.14. In terms of profitability, ACCD's ROE is -0.22%, compared to WORX's ROE of -0.73%. Regarding short-term risk, ACCD is less volatile compared to WORX. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check WORX's competition here
ACCD vs MSPR Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, MSPR has a market cap of 427K. Regarding current trading prices, ACCD is priced at $7.02, while MSPR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas MSPR's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to MSPR's ROE of +3.93%. Regarding short-term risk, ACCD is less volatile compared to MSPR. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check MSPR's competition here
ACCD vs WGSWW Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, WGSWW has a market cap of 226.3K. Regarding current trading prices, ACCD is priced at $7.02, while WGSWW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas WGSWW's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to WGSWW's ROE of -0.07%. Regarding short-term risk, ACCD is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check WGSWW's competition here
ACCD vs KERN Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, ACCD is priced at $7.02, while KERN trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas KERN's P/E ratio is -0.01. In terms of profitability, ACCD's ROE is -0.22%, compared to KERN's ROE of -0.02%. Regarding short-term risk, ACCD is less volatile compared to KERN. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check KERN's competition here
ACCD vs KERNW Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, ACCD is priced at $7.02, while KERNW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas KERNW's P/E ratio is -0.00. In terms of profitability, ACCD's ROE is -0.22%, compared to KERNW's ROE of -0.02%. Regarding short-term risk, ACCD is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check KERNW's competition here
ACCD vs LIFWW Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, ACCD is priced at $7.02, while LIFWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas LIFWW's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to LIFWW's ROE of +3.93%. Regarding short-term risk, ACCD and LIFWW have similar daily volatility (0.00).Check LIFWW's competition here
ACCD vs OTRKP Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, OTRKP has a market cap of 50.1K. Regarding current trading prices, ACCD is priced at $7.02, while OTRKP trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas OTRKP's P/E ratio is -0.00. In terms of profitability, ACCD's ROE is -0.22%, compared to OTRKP's ROE of -1.66%. Regarding short-term risk, ACCD is less volatile compared to OTRKP. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check OTRKP's competition here
ACCD vs CMAXW Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, ACCD is priced at $7.02, while CMAXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas CMAXW's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, ACCD and CMAXW have similar daily volatility (0.00).Check CMAXW's competition here
ACCD vs ACONW Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, ACONW has a market cap of 17.7K. Regarding current trading prices, ACCD is priced at $7.02, while ACONW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas ACONW's P/E ratio is -0.01. In terms of profitability, ACCD's ROE is -0.22%, compared to ACONW's ROE of -0.00%. Regarding short-term risk, ACCD is less volatile compared to ACONW. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check ACONW's competition here
ACCD vs ICCT Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, ICCT has a market cap of 9.8K. Regarding current trading prices, ACCD is priced at $7.02, while ICCT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas ICCT's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to ICCT's ROE of +11.65%. Regarding short-term risk, ACCD is less volatile compared to ICCT. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check ICCT's competition here
ACCD vs FOXO Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, FOXO has a market cap of 3K. Regarding current trading prices, ACCD is priced at $7.02, while FOXO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas FOXO's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to FOXO's ROE of -0.80%. Regarding short-term risk, ACCD and FOXO have similar daily volatility (0.00).Check FOXO's competition here
ACCD vs MSPRW Comparison April 2026
ACCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, MSPRW has a market cap of 2.8K. Regarding current trading prices, ACCD is priced at $7.02, while MSPRW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas MSPRW's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to MSPRW's ROE of +3.93%. Regarding short-term risk, ACCD is less volatile compared to MSPRW. This indicates potentially lower risk in terms of short-term price fluctuations for ACCD.Check MSPRW's competition here